Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

Where Big Pharma is betting big in the M&A boom

29 July 2026 Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?

Careers

Fish & Richardson adds AI and medical device specialist

29 July 2026 The engineer-turned-lawyer joins as a principal, bringing 15 years of experience advising on patent strategy across AI, software, and medical devices.

MedTech

Boston Scientific overturns $42m patent verdict on appeal

28 July 2026 Years of litigation over biodegradable drug-delivery technology took another turn after the Federal Circuit delivered a significant win for the medical device maker.

More features

Trump slaps 100% tariff on generic drugs in US manufacturing push

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

‘Blatant imitation’: Indian court blocks copycat pharma branding

US life sciences damages averaged $33.5m between 2019-2025

Chadha & Chadha hires former Remfry & Sagar patent partner

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Part I: Ozempic goes generic as Novo’s key patent expires

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features